Allylestrenol
Based on 1 publication(s) in Google Scholar
Allylestrenol is an orally active synthetic anti-androgen sexualsteroid. Allylestrenol can prevent miscarriage in vivo. Allylestrenol significantly affects testosterone progesterone level in rat model. Allylestrenol can reduce ventral prostate weight in rat model.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.91%
- No. CAS: 432-60-0
- Fòrmula: C21H32O
- Peso molecular:300.48
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Allylestrenol
More
Actividad biológica
Allylestrenol (0.6 mg/males, single dose) significantly elevates the testosterone level in male rats[1].
Allylestrenol (1-100 mg/kg/day, p.o., once daily for 14 d) reduces the weights of ventral prostate and seminal vesicles in a dose-dependent manner in castrated immature rats[2].
Allylestrenol (1-30 mg/kg/day, p.o., once daily for 21 d) reduces the weights of the ventral prostate (15-71%) and seminal vesicles (13-96%) dose-dependently, and leads to marked reductions in both the prostatic testosterone and 5α-dihydrotestosterone contents in mature male rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Castrated immature rats[2]
-
Dosage:1, 10, 100 mg/kg
-
Administration:Oral gavage (p.o.)
-
Result:Reduced the weights of ventral prostate by 17%, 14% and 45%.
Reduced seminal vesicles by 20%, 33%, and 57%.
Chemical Information
-
No. CAS 432-60-0
-
Appearance Solid
-
Peso molecular 300.48
-
Fòrmula C21H32O
-
Color White to off-white
-
SMILES
C[C@@]12[C@](O)(CC=C)CC[C@@]1([H])[C@]3([H])CCC4=CCCC[C@]4([H])[C@@]3([H])CC2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvente y solubilidad
DMSO : ≥ 50 mg/mL (166.40 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Pap E, et al. Effect of prenatal allylestrenol treatment (hormonal imprinting) on the serum testosterone and progesterone level in adult rats. Gen Pharmacol. 1995 Mar;26(2):365-7. [Content Brief]
[2]. Yasuda, N., et al., (1997). Effects of steroid 5alpha-reductase inhibitor ONO-9302 and anti-androgen allylestrenol on the prostatic growth, and plasma and prostatic hormone levels in rats. Japanese journal of pharmacology, 74(3), 243–252. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3280 mL | 16.6400 mL | 33.2801 mL | 83.2002 mL |
| 5 mM | 0.6656 mL | 3.3280 mL | 6.6560 mL | 16.6400 mL | |
| 10 mM | 0.3328 mL | 1.6640 mL | 3.3280 mL | 8.3200 mL | |
| 15 mM | 0.2219 mL | 1.1093 mL | 2.2187 mL | 5.5467 mL | |
| 20 mM | 0.1664 mL | 0.8320 mL | 1.6640 mL | 4.1600 mL | |
| 25 mM | 0.1331 mL | 0.6656 mL | 1.3312 mL | 3.3280 mL | |
| 30 mM | 0.1109 mL | 0.5547 mL | 1.1093 mL | 2.7733 mL | |
| 40 mM | 0.0832 mL | 0.4160 mL | 0.8320 mL | 2.0800 mL | |
| 50 mM | 0.0666 mL | 0.3328 mL | 0.6656 mL | 1.6640 mL | |
| 60 mM | 0.0555 mL | 0.2773 mL | 0.5547 mL | 1.3867 mL | |
| 80 mM | 0.0416 mL | 0.2080 mL | 0.4160 mL | 1.0400 mL | |
| 100 mM | 0.0333 mL | 0.1664 mL | 0.3328 mL | 0.8320 mL |